Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation. [electronic resource]
Producer: 20091013Description: 791-801 p. digitalISSN:- 1179-1969
- Aged
- Antiparkinson Agents -- economics
- Benzothiazoles -- economics
- Clinical Trials as Topic
- Cost-Benefit Analysis
- Disease Progression
- Dopamine Agonists -- economics
- Female
- Health Care Costs
- Humans
- Indans -- economics
- Insurance, Health, Reimbursement
- Male
- Markov Chains
- Middle Aged
- Models, Economic
- Monoamine Oxidase Inhibitors -- economics
- Monte Carlo Method
- Parkinson Disease -- drug therapy
- Pramipexole
- Probability
- Quality-Adjusted Life Years
- State Medicine
- Treatment Outcome
- United Kingdom
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.